A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Intravenous Infusion Study to Assess the Safety, Tolerability and Pharmacokinetics of DUR-928 in Healthy Volunteers

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Intravenous Infusion Study to Assess the Safety, Tolerability and Pharmacokinetics of DUR-928 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs DUR 928 (Primary)
  • Indications Acute kidney injury
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 13 Sep 2016 Status changed from recruiting to completed.
    • 04 Aug 2016 Status changed from not yet recruiting to recruiting.
    • 12 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top